{
  "success": true,
  "pagesUsed": [
    15,
    16,
    17,
    18,
    19,
    20,
    40,
    41,
    42,
    43,
    44,
    45
  ],
  "modelUsed": "gemini-3-flash-preview",
  "eligibility": {
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Informed Consent",
        "text": "Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written informed consent and privacy language as per national regulations (e.g., Health Insurance Portability Accountability Act authorization for United States sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "Adult Status",
        "text": "Subject is considered an adult according to local regulation at the time of signing informed consent.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "Histological Diagnosis",
        "text": "Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology. Specific to subjects enrolled in France, histological diagnosis is required.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "Metastatic Disease Documentation",
        "text": "Subject has metastatic prostate cancer documented by positive bone scan (for bone disease) or metastatic lesions on CT or MRI scan (for soft tissue). Subjects whose disease spread is limited to regional pelvic lymph nodes are not eligible.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "ADT Maintenance",
        "text": "Once randomized at day 1, subject must maintain ADT with an LHRH agonist or antagonist during study treatment or have a history of bilateral orchiectomy (i.e., medical or surgical castration).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "ECOG Performance Status",
        "text": "Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "Life Expectancy",
        "text": "Subject has an estimated life expectancy of ≥ 12 months as assessed by the investigator.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "Drug Administration Compliance",
        "text": "Subject is able to swallow the study drug and comply with study requirements.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Contraception Requirements",
        "text": "A sexually active male subject and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception) from screening through 3 months after the last dose of study drug. Two acceptable methods of birth control include condom (barrier method is required) AND 1 of the following: Consistent and correct usage of established, proper use of hormonal contraceptives that inhibit ovulation by the female partner; Established intrauterine device or intrauterine system by the female partner; Tubal ligation in the female partner performed at least 6 months prior to subject’s screening visit; Vasectomy or other procedure resulting in infertility (e.g., bilateral orchiectomy) performed at least 6 months prior to screening; Calendar-based contraceptive methods (Knaus-Ogino or rhythm method applicable to subjects enrolled in Japan only).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_10",
        "name": "Condom Use with Pregnant Partner",
        "text": "Subject must use a condom throughout the study if engaging in sexual intercourse with a pregnant woman.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_11",
        "name": "Sperm Donation Restriction",
        "text": "Subject must agree not to donate sperm from first dose of study drug through 3 months after the last dose of study drug.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_12",
        "name": "Interventional Study Restriction",
        "text": "Subject agrees not to participate in another interventional study while on treatment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_13",
        "name": "Prior Therapy Exclusion",
        "text": "Subject has received any prior pharmacotherapy, radiation therapy or surgery for metastatic prostate cancer (the following exceptions are permitted): Up to 3 months of ADT with LHRH agonists or antagonists or orchiectomy with or without concurrent antiandrogens prior to day 1, with no radiographic evidence of disease progression or rising PSA levels prior to day 1; Subject may have 1 course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 4 weeks prior to day 1; Up to 6 cycles of docetaxel therapy with final treatment administration completed within 2 months of day 1 and no evidence of disease progression during or after the completion of docetaxel therapy; Up to 6 months of ADT with LHRH agonists or antagonists or orchiectomy with or without concurrent antiandrogens prior to day 1 if subject was treated with docetaxel, with no radiographic evidence of disease progression or rising PSA levels prior to day 1; Prior ADT given for < 39 months in duration and > 9 months before randomization as neoadjuvant/adjuvant therapy.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_14",
        "name": "Major Surgery",
        "text": "Subject had a major surgery within 4 weeks prior to day 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_15",
        "name": "5-alpha Reductase Inhibitors",
        "text": "Subject received treatment with 5-α reductase inhibitors (finasteride, dutasteride) within 4 weeks prior to day 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_16",
        "name": "Hormonal Therapy",
        "text": "Subject received treatment with estrogens, cyprotoerone acetate or androgens within 4 weeks prior to day 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_17",
        "name": "Systemic Glucocorticoids",
        "text": "Subject received treatment with systemic glucocorticoids greater than the equivalent of 10 mg per day of prednisone within 4 weeks prior to day 1, intended for the treatment of prostate cancer.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_18",
        "name": "Herbal Medications",
        "text": "Subject received treatment with herbal medications that have known hormonal antiprostate cancer activity and/or are known to decrease PSA levels within 4 weeks prior to day 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_19",
        "name": "Specific Prior Prostate Cancer Agents",
        "text": "Subject received prior aminoglutethimide, ketoconazole, abiraterone acetate or enzalutamide for the treatment of prostate cancer or participation in a clinical study of an investigational agent that inhibits the AR or androgen synthesis (e.g., TAK-700, ARN-509, ODM-201).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_20",
        "name": "Investigational Agent",
        "text": "Subject received investigational agent within 4 weeks prior to day 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_21",
        "name": "Brain Metastasis",
        "text": "Subject has known or suspected brain metastasis or active leptomeningeal disease.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_22",
        "name": "Other Invasive Cancer",
        "text": "Subject has a history of another invasive cancer within 3 years of screening, with the exception of fully treated cancers with a remote probability of recurrence based on investigator assessment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_23",
        "name": "Hematology Parameters",
        "text": "Subject has absolute neutrophil count < 1500/μL, platelet count < 100000/μL or hemoglobin < 10 g/dL (6.2 mmol/L) at screening. NOTE: May not have received any growth factors within 7 days or blood transfusions within 28 days prior to the hematology values obtained at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_24",
        "name": "Liver Function",
        "text": "Subject has total bilirubin (TBL) ≥ 1.5 x the upper limit of normal (ULN) (except subjects with documented Gilbert’s disease), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 x the ULN at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_25",
        "name": "Renal Function",
        "text": "Subject has creatinine > 2 mg/dL (177 μmol/L) at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_26",
        "name": "Albumin Levels",
        "text": "Subject has albumin < 3.0 g/dL (30 g/L) at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_27",
        "name": "Seizure History",
        "text": "Subject has a history of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma, brain arteriovenous malformation).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_28",
        "name": "Loss of Consciousness/TIA",
        "text": "Subject has history of loss of consciousness or transient ischemic attack within 12 months prior to day 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_29",
        "name": "Cardiovascular Disease",
        "text": "Subject has clinically significant cardiovascular disease, including the following: Myocardial infarction within 6 months prior to screening; Unstable angina within 3 months prior to screening; New York Heart Association class III or IV congestive heart failure or a history of New York Heart Association class III or IV congestive heart failure unless a screening echocardiogram or multigated acquisition scan performed within 3 months before the randomization date demonstrates a left ventricular ejection fraction ≥ 45%; History of clinically significant ventricular arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes); History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place; Hypotension as indicated by systolic blood pressure < 86 mm Hg at screening; Bradycardia as indicated by a heart rate of ≤ 45 beats per minute on the screening ECG; Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_30",
        "name": "Gastrointestinal Disorder",
        "text": "Subject has gastrointestinal disorder affecting absorption.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_31",
        "name": "Concurrent Conditions",
        "text": "Subject has any concurrent disease, infection or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data in the opinion of the investigator.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_32",
        "name": "Bisphosphonates/Denosumab",
        "text": "Subject received bisphosphonates or denosumab within 2 weeks prior to day 1 unless administered at stable dose or to treat diagnosed osteoporosis.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_33",
        "name": "Hypersensitivity",
        "text": "Subject has shown a hypersensitivity reaction to the active pharmaceutical ingredient or any of the study capsule components, including Labrasol®, butylated hydroxyanisole (BHA), and butylated hydroxytoluene (BHT).",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion",
        "name": "Informed Consent",
        "nextId": "ec_2"
      },
      {
        "id": "ec_2",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion",
        "name": "Adult Status",
        "previousId": "ec_1",
        "nextId": "ec_3"
      },
      {
        "id": "ec_3",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion",
        "name": "Histological Diagnosis",
        "previousId": "ec_2",
        "nextId": "ec_4"
      },
      {
        "id": "ec_4",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion",
        "name": "Metastatic Disease Documentation",
        "previousId": "ec_3",
        "nextId": "ec_5"
      },
      {
        "id": "ec_5",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion",
        "name": "ADT Maintenance",
        "previousId": "ec_4",
        "nextId": "ec_6"
      },
      {
        "id": "ec_6",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion",
        "name": "ECOG Performance Status",
        "previousId": "ec_5",
        "nextId": "ec_7"
      },
      {
        "id": "ec_7",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion",
        "name": "Life Expectancy",
        "previousId": "ec_6",
        "nextId": "ec_8"
      },
      {
        "id": "ec_8",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion",
        "name": "Drug Administration Compliance",
        "previousId": "ec_7",
        "nextId": "ec_9"
      },
      {
        "id": "ec_9",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion",
        "name": "Contraception Requirements",
        "previousId": "ec_8",
        "nextId": "ec_10"
      },
      {
        "id": "ec_10",
        "identifier": "10",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_10",
        "instanceType": "EligibilityCriterion",
        "name": "Condom Use with Pregnant Partner",
        "previousId": "ec_9",
        "nextId": "ec_11"
      },
      {
        "id": "ec_11",
        "identifier": "11",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_11",
        "instanceType": "EligibilityCriterion",
        "name": "Sperm Donation Restriction",
        "previousId": "ec_10",
        "nextId": "ec_12"
      },
      {
        "id": "ec_12",
        "identifier": "12",
        "category": {
          "code": "Inclusion",
          "codeSystem": "USDM",
          "decode": "Inclusion"
        },
        "criterionItemId": "eci_12",
        "instanceType": "EligibilityCriterion",
        "name": "Interventional Study Restriction",
        "previousId": "ec_11"
      },
      {
        "id": "ec_13",
        "identifier": "1",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_13",
        "instanceType": "EligibilityCriterion",
        "name": "Prior Therapy Exclusion",
        "nextId": "ec_14"
      },
      {
        "id": "ec_14",
        "identifier": "2",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_14",
        "instanceType": "EligibilityCriterion",
        "name": "Major Surgery",
        "previousId": "ec_13",
        "nextId": "ec_15"
      },
      {
        "id": "ec_15",
        "identifier": "3",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_15",
        "instanceType": "EligibilityCriterion",
        "name": "5-alpha Reductase Inhibitors",
        "previousId": "ec_14",
        "nextId": "ec_16"
      },
      {
        "id": "ec_16",
        "identifier": "4",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_16",
        "instanceType": "EligibilityCriterion",
        "name": "Hormonal Therapy",
        "previousId": "ec_15",
        "nextId": "ec_17"
      },
      {
        "id": "ec_17",
        "identifier": "5",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_17",
        "instanceType": "EligibilityCriterion",
        "name": "Systemic Glucocorticoids",
        "previousId": "ec_16",
        "nextId": "ec_18"
      },
      {
        "id": "ec_18",
        "identifier": "6",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_18",
        "instanceType": "EligibilityCriterion",
        "name": "Herbal Medications",
        "previousId": "ec_17",
        "nextId": "ec_19"
      },
      {
        "id": "ec_19",
        "identifier": "7",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_19",
        "instanceType": "EligibilityCriterion",
        "name": "Specific Prior Prostate Cancer Agents",
        "previousId": "ec_18",
        "nextId": "ec_20"
      },
      {
        "id": "ec_20",
        "identifier": "8",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_20",
        "instanceType": "EligibilityCriterion",
        "name": "Investigational Agent",
        "previousId": "ec_19",
        "nextId": "ec_21"
      },
      {
        "id": "ec_21",
        "identifier": "9",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_21",
        "instanceType": "EligibilityCriterion",
        "name": "Brain Metastasis",
        "previousId": "ec_20",
        "nextId": "ec_22"
      },
      {
        "id": "ec_22",
        "identifier": "10",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_22",
        "instanceType": "EligibilityCriterion",
        "name": "Other Invasive Cancer",
        "previousId": "ec_21",
        "nextId": "ec_23"
      },
      {
        "id": "ec_23",
        "identifier": "11",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_23",
        "instanceType": "EligibilityCriterion",
        "name": "Hematology Parameters",
        "previousId": "ec_22",
        "nextId": "ec_24"
      },
      {
        "id": "ec_24",
        "identifier": "12",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_24",
        "instanceType": "EligibilityCriterion",
        "name": "Liver Function",
        "previousId": "ec_23",
        "nextId": "ec_25"
      },
      {
        "id": "ec_25",
        "identifier": "13",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_25",
        "instanceType": "EligibilityCriterion",
        "name": "Renal Function",
        "previousId": "ec_24",
        "nextId": "ec_26"
      },
      {
        "id": "ec_26",
        "identifier": "14",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_26",
        "instanceType": "EligibilityCriterion",
        "name": "Albumin Levels",
        "previousId": "ec_25",
        "nextId": "ec_27"
      },
      {
        "id": "ec_27",
        "identifier": "15",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_27",
        "instanceType": "EligibilityCriterion",
        "name": "Seizure History",
        "previousId": "ec_26",
        "nextId": "ec_28"
      },
      {
        "id": "ec_28",
        "identifier": "16",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_28",
        "instanceType": "EligibilityCriterion",
        "name": "Loss of Consciousness/TIA",
        "previousId": "ec_27",
        "nextId": "ec_29"
      },
      {
        "id": "ec_29",
        "identifier": "17",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_29",
        "instanceType": "EligibilityCriterion",
        "name": "Cardiovascular Disease",
        "previousId": "ec_28",
        "nextId": "ec_30"
      },
      {
        "id": "ec_30",
        "identifier": "18",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_30",
        "instanceType": "EligibilityCriterion",
        "name": "Gastrointestinal Disorder",
        "previousId": "ec_29",
        "nextId": "ec_31"
      },
      {
        "id": "ec_31",
        "identifier": "19",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_31",
        "instanceType": "EligibilityCriterion",
        "name": "Concurrent Conditions",
        "previousId": "ec_30",
        "nextId": "ec_32"
      },
      {
        "id": "ec_32",
        "identifier": "20",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_32",
        "instanceType": "EligibilityCriterion",
        "name": "Bisphosphonates/Denosumab",
        "previousId": "ec_31",
        "nextId": "ec_33"
      },
      {
        "id": "ec_33",
        "identifier": "21",
        "category": {
          "code": "Exclusion",
          "codeSystem": "USDM",
          "decode": "Exclusion"
        },
        "criterionItemId": "eci_33",
        "instanceType": "EligibilityCriterion",
        "name": "Hypersensitivity",
        "previousId": "ec_32"
      }
    ],
    "summary": {
      "inclusionCount": 12,
      "exclusionCount": 21,
      "totalCount": 33
    },
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9",
        "ec_10",
        "ec_11",
        "ec_12",
        "ec_13",
        "ec_14",
        "ec_15",
        "ec_16",
        "ec_17",
        "ec_18",
        "ec_19",
        "ec_20",
        "ec_21",
        "ec_22",
        "ec_23",
        "ec_24",
        "ec_25",
        "ec_26",
        "ec_27",
        "ec_28",
        "ec_29",
        "ec_30",
        "ec_31",
        "ec_32",
        "ec_33"
      ],
      "instanceType": "StudyDesignPopulation",
      "description": "Target population defined by eligibility criteria"
    }
  },
  "rawResponse": {
    "eligibilityCriteria": [
      {
        "id": "ec_1",
        "name": "Informed Consent",
        "identifier": "1",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_1",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_2",
        "name": "Adult Status",
        "identifier": "2",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_2",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_3",
        "name": "Histological Diagnosis",
        "identifier": "3",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_3",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_4",
        "name": "Metastatic Disease Documentation",
        "identifier": "4",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_4",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_5",
        "name": "ADT Maintenance",
        "identifier": "5",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_5",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_6",
        "name": "ECOG Performance Status",
        "identifier": "6",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_6",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_7",
        "name": "Life Expectancy",
        "identifier": "7",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_7",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_8",
        "name": "Drug Administration Compliance",
        "identifier": "8",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_8",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_9",
        "name": "Contraception Requirements",
        "identifier": "9",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_9",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_10",
        "name": "Condom Use with Pregnant Partner",
        "identifier": "10",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_10",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_11",
        "name": "Sperm Donation Restriction",
        "identifier": "11",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_11",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_12",
        "name": "Interventional Study Restriction",
        "identifier": "12",
        "category": {
          "code": "Inclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Inclusion Criterion"
        },
        "criterionItemId": "eci_12",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_13",
        "name": "Prior Therapy Exclusion",
        "identifier": "1",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_13",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_14",
        "name": "Major Surgery",
        "identifier": "2",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_14",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_15",
        "name": "5-alpha Reductase Inhibitors",
        "identifier": "3",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_15",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_16",
        "name": "Hormonal Therapy",
        "identifier": "4",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_16",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_17",
        "name": "Systemic Glucocorticoids",
        "identifier": "5",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_17",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_18",
        "name": "Herbal Medications",
        "identifier": "6",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_18",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_19",
        "name": "Specific Prior Prostate Cancer Agents",
        "identifier": "7",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_19",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_20",
        "name": "Investigational Agent",
        "identifier": "8",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_20",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_21",
        "name": "Brain Metastasis",
        "identifier": "9",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_21",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_22",
        "name": "Other Invasive Cancer",
        "identifier": "10",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_22",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_23",
        "name": "Hematology Parameters",
        "identifier": "11",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_23",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_24",
        "name": "Liver Function",
        "identifier": "12",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_24",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_25",
        "name": "Renal Function",
        "identifier": "13",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_25",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_26",
        "name": "Albumin Levels",
        "identifier": "14",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_26",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_27",
        "name": "Seizure History",
        "identifier": "15",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_27",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_28",
        "name": "Loss of Consciousness/TIA",
        "identifier": "16",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_28",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_29",
        "name": "Cardiovascular Disease",
        "identifier": "17",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_29",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_30",
        "name": "Gastrointestinal Disorder",
        "identifier": "18",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_30",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_31",
        "name": "Concurrent Conditions",
        "identifier": "19",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_31",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_32",
        "name": "Bisphosphonates/Denosumab",
        "identifier": "20",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_32",
        "instanceType": "EligibilityCriterion"
      },
      {
        "id": "ec_33",
        "name": "Hypersensitivity",
        "identifier": "21",
        "category": {
          "code": "Exclusion",
          "codeSystem": "http://www.cdisc.org/USDM/criterionCategory",
          "decode": "Exclusion Criterion"
        },
        "criterionItemId": "eci_33",
        "instanceType": "EligibilityCriterion"
      }
    ],
    "eligibilityCriterionItems": [
      {
        "id": "eci_1",
        "name": "Informed Consent",
        "text": "Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written informed consent and privacy language as per national regulations (e.g., Health Insurance Portability Accountability Act authorization for United States sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_2",
        "name": "Adult Status",
        "text": "Subject is considered an adult according to local regulation at the time of signing informed consent.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_3",
        "name": "Histological Diagnosis",
        "text": "Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology. Specific to subjects enrolled in France, histological diagnosis is required.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_4",
        "name": "Metastatic Disease Documentation",
        "text": "Subject has metastatic prostate cancer documented by positive bone scan (for bone disease) or metastatic lesions on CT or MRI scan (for soft tissue). Subjects whose disease spread is limited to regional pelvic lymph nodes are not eligible.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_5",
        "name": "ADT Maintenance",
        "text": "Once randomized at day 1, subject must maintain ADT with an LHRH agonist or antagonist during study treatment or have a history of bilateral orchiectomy (i.e., medical or surgical castration).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_6",
        "name": "ECOG Performance Status",
        "text": "Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_7",
        "name": "Life Expectancy",
        "text": "Subject has an estimated life expectancy of ≥ 12 months as assessed by the investigator.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_8",
        "name": "Drug Administration Compliance",
        "text": "Subject is able to swallow the study drug and comply with study requirements.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_9",
        "name": "Contraception Requirements",
        "text": "A sexually active male subject and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception) from screening through 3 months after the last dose of study drug. Two acceptable methods of birth control include condom (barrier method is required) AND 1 of the following: Consistent and correct usage of established, proper use of hormonal contraceptives that inhibit ovulation by the female partner; Established intrauterine device or intrauterine system by the female partner; Tubal ligation in the female partner performed at least 6 months prior to subject’s screening visit; Vasectomy or other procedure resulting in infertility (e.g., bilateral orchiectomy) performed at least 6 months prior to screening; Calendar-based contraceptive methods (Knaus-Ogino or rhythm method applicable to subjects enrolled in Japan only).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_10",
        "name": "Condom Use with Pregnant Partner",
        "text": "Subject must use a condom throughout the study if engaging in sexual intercourse with a pregnant woman.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_11",
        "name": "Sperm Donation Restriction",
        "text": "Subject must agree not to donate sperm from first dose of study drug through 3 months after the last dose of study drug.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_12",
        "name": "Interventional Study Restriction",
        "text": "Subject agrees not to participate in another interventional study while on treatment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_13",
        "name": "Prior Therapy Exclusion",
        "text": "Subject has received any prior pharmacotherapy, radiation therapy or surgery for metastatic prostate cancer (the following exceptions are permitted): Up to 3 months of ADT with LHRH agonists or antagonists or orchiectomy with or without concurrent antiandrogens prior to day 1, with no radiographic evidence of disease progression or rising PSA levels prior to day 1; Subject may have 1 course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 4 weeks prior to day 1; Up to 6 cycles of docetaxel therapy with final treatment administration completed within 2 months of day 1 and no evidence of disease progression during or after the completion of docetaxel therapy; Up to 6 months of ADT with LHRH agonists or antagonists or orchiectomy with or without concurrent antiandrogens prior to day 1 if subject was treated with docetaxel, with no radiographic evidence of disease progression or rising PSA levels prior to day 1; Prior ADT given for < 39 months in duration and > 9 months before randomization as neoadjuvant/adjuvant therapy.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_14",
        "name": "Major Surgery",
        "text": "Subject had a major surgery within 4 weeks prior to day 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_15",
        "name": "5-alpha Reductase Inhibitors",
        "text": "Subject received treatment with 5-α reductase inhibitors (finasteride, dutasteride) within 4 weeks prior to day 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_16",
        "name": "Hormonal Therapy",
        "text": "Subject received treatment with estrogens, cyprotoerone acetate or androgens within 4 weeks prior to day 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_17",
        "name": "Systemic Glucocorticoids",
        "text": "Subject received treatment with systemic glucocorticoids greater than the equivalent of 10 mg per day of prednisone within 4 weeks prior to day 1, intended for the treatment of prostate cancer.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_18",
        "name": "Herbal Medications",
        "text": "Subject received treatment with herbal medications that have known hormonal antiprostate cancer activity and/or are known to decrease PSA levels within 4 weeks prior to day 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_19",
        "name": "Specific Prior Prostate Cancer Agents",
        "text": "Subject received prior aminoglutethimide, ketoconazole, abiraterone acetate or enzalutamide for the treatment of prostate cancer or participation in a clinical study of an investigational agent that inhibits the AR or androgen synthesis (e.g., TAK-700, ARN-509, ODM-201).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_20",
        "name": "Investigational Agent",
        "text": "Subject received investigational agent within 4 weeks prior to day 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_21",
        "name": "Brain Metastasis",
        "text": "Subject has known or suspected brain metastasis or active leptomeningeal disease.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_22",
        "name": "Other Invasive Cancer",
        "text": "Subject has a history of another invasive cancer within 3 years of screening, with the exception of fully treated cancers with a remote probability of recurrence based on investigator assessment.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_23",
        "name": "Hematology Parameters",
        "text": "Subject has absolute neutrophil count < 1500/μL, platelet count < 100000/μL or hemoglobin < 10 g/dL (6.2 mmol/L) at screening. NOTE: May not have received any growth factors within 7 days or blood transfusions within 28 days prior to the hematology values obtained at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_24",
        "name": "Liver Function",
        "text": "Subject has total bilirubin (TBL) ≥ 1.5 x the upper limit of normal (ULN) (except subjects with documented Gilbert’s disease), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 x the ULN at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_25",
        "name": "Renal Function",
        "text": "Subject has creatinine > 2 mg/dL (177 μmol/L) at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_26",
        "name": "Albumin Levels",
        "text": "Subject has albumin < 3.0 g/dL (30 g/L) at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_27",
        "name": "Seizure History",
        "text": "Subject has a history of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma, brain arteriovenous malformation).",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_28",
        "name": "Loss of Consciousness/TIA",
        "text": "Subject has history of loss of consciousness or transient ischemic attack within 12 months prior to day 1.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_29",
        "name": "Cardiovascular Disease",
        "text": "Subject has clinically significant cardiovascular disease, including the following: Myocardial infarction within 6 months prior to screening; Unstable angina within 3 months prior to screening; New York Heart Association class III or IV congestive heart failure or a history of New York Heart Association class III or IV congestive heart failure unless a screening echocardiogram or multigated acquisition scan performed within 3 months before the randomization date demonstrates a left ventricular ejection fraction ≥ 45%; History of clinically significant ventricular arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes); History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place; Hypotension as indicated by systolic blood pressure < 86 mm Hg at screening; Bradycardia as indicated by a heart rate of ≤ 45 beats per minute on the screening ECG; Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg at screening.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_30",
        "name": "Gastrointestinal Disorder",
        "text": "Subject has gastrointestinal disorder affecting absorption.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_31",
        "name": "Concurrent Conditions",
        "text": "Subject has any concurrent disease, infection or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data in the opinion of the investigator.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_32",
        "name": "Bisphosphonates/Denosumab",
        "text": "Subject received bisphosphonates or denosumab within 2 weeks prior to day 1 unless administered at stable dose or to treat diagnosed osteoporosis.",
        "instanceType": "EligibilityCriterionItem"
      },
      {
        "id": "eci_33",
        "name": "Hypersensitivity",
        "text": "Subject has shown a hypersensitivity reaction to the active pharmaceutical ingredient or any of the study capsule components, including Labrasol®, butylated hydroxyanisole (BHA), and butylated hydroxytoluene (BHT).",
        "instanceType": "EligibilityCriterionItem"
      }
    ],
    "population": {
      "id": "pop_1",
      "name": "Study Population",
      "includesHealthySubjects": false,
      "plannedEnrollmentNumber": {
        "maxValue": 1100,
        "instanceType": "Range"
      },
      "plannedMinimumAge": null,
      "plannedMaximumAge": null,
      "plannedSex": [
        {
          "code": "Male",
          "codeSystem": "http://www.cdisc.org/USDM/sex",
          "decode": "Male"
        }
      ],
      "criterionIds": [
        "ec_1",
        "ec_2",
        "ec_3",
        "ec_4",
        "ec_5",
        "ec_6",
        "ec_7",
        "ec_8",
        "ec_9",
        "ec_10",
        "ec_11",
        "ec_12",
        "ec_13",
        "ec_14",
        "ec_15",
        "ec_16",
        "ec_17",
        "ec_18",
        "ec_19",
        "ec_20",
        "ec_21",
        "ec_22",
        "ec_23",
        "ec_24",
        "ec_25",
        "ec_26",
        "ec_27",
        "ec_28",
        "ec_29",
        "ec_30",
        "ec_31",
        "ec_32",
        "ec_33"
      ],
      "instanceType": "StudyDesignPopulation"
    }
  }
}